{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:12:54Z","timestamp":1791231174612,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder that progresses to multiple myeloma (MM), or other plasma-cell or lymphoid disorders at a rate of 1%\/year. We evaluate the contribution of body mass index (BMI) to MGUS progression beyond established clinical factors in a population-based study. We identified 594 MGUS through a population-based screening study in Olmsted County, Minnesota, between 1995 and 2003. Follow-up time was calculated from the date of MGUS to last follow-up, death, or progression to MM\/another plasma-cell\/lymphoid disorder. BMI (kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    \u2009&lt;\u200925\/\u226525) was measured close to screening date. We used Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of BMI\u2009\u2265\u200925 versus BMI\u2009&lt;\u200925 with MGUS progression and also evaluated the corresponding c-statistic and 95% CI to describe discrimination of the model for MGUS progression. Median follow-up was 10.5 years (range:0\u201325), while 465 patients died and 57 progressed and developed MM (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200939), AL amyloidosis (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20098), lymphoma (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20095), or Waldenstrom-macroglobulinemia (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20095). In univariate analyses, BMI\u2009\u2265\u200925 (HR\u2009=\u20092.14,CI:1.05\u20134.36,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.04), non-IgG (HR\u2009=\u20092.84, CI:1.68\u20134.80,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0001), high monoclonal (M) protein (HR\u2009=\u20092.57, CI:1.50\u20134.42,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.001), and abnormal free light chain ratio (FLC\n                    <jats:sub>r<\/jats:sub>\n                    ) (HR\u2009=\u20093.39, CI:1.98\u20135.82,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001) were associated with increased risk of MGUS progression, and were independently associated in a multivariable model (c-statistic\u2009=\u20090.75, CI:0.68\u20130.82). The BMI association was stronger among females (HR\u2009=\u20093.55, CI:1.06\u201311.9,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.04) vs. males (HR\u2009=\u20091.39, CI:0.57\u20133.36,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.47), although the interaction between BMI and sex was not significant (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.15). In conclusion, high BMI is a prognostic factor for MGUS progression, independent of isotype, M protein, and FLC\n                    <jats:sub>r<\/jats:sub>\n                    . This association may be stronger among females.\n                  <\/jats:p>","DOI":"10.1038\/s41408-022-00659-9","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T05:03:25Z","timestamp":1650344605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota"],"prefix":"10.1038","volume":"12","author":[{"given":"Geffen","family":"Kleinstern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-2124","authenticated-orcid":false,"given":"Dirk R.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Allmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-1074","authenticated-orcid":false,"given":"Grace","family":"Muntifering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1964-5522","authenticated-orcid":false,"given":"Jason","family":"Sinnwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-4712","authenticated-orcid":false,"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1962-9322","authenticated-orcid":false,"given":"Celine M.","family":"Vachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"659_CR1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121\u20137.","journal-title":"Leukemia."},{"key":"659_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241\u20139.","journal-title":"N Engl J Med"},{"key":"659_CR3","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Publications; 2008."},{"key":"659_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","volume":"123","author":"I Turesson","year":"2014","unstructured":"Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123:338\u201345.","journal-title":"Blood."},{"key":"659_CR5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362\u20139.","journal-title":"N Engl J Med"},{"key":"659_CR6","first-page":"578","volume":"25","author":"RA Kyle","year":"2011","unstructured":"Kyle RA, Rajkumar SV. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology. 2011;25:578\u201386.","journal-title":"Oncology"},{"key":"659_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/BF01694762","volume":"5","author":"GD Friedman","year":"1994","unstructured":"Friedman GD, Herrinton LJ. Obesity and multiple myeloma. Cancer Causes Control. 1994;5:479\u201383.","journal-title":"Cancer Causes Control"},{"key":"659_CR8","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1158\/1055-9965.EPI-07-0143","volume":"16","author":"BM Birmann","year":"2007","unstructured":"Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomark Prev. 2007;16:1474\u20138.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"659_CR9","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ejca.2011.01.020","volume":"47","author":"A Wallin","year":"2011","unstructured":"Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: A meta-analysis of prospective studies. Eur J Cancer. 2011;47:1606\u201315.","journal-title":"Eur J Cancer"},{"key":"659_CR10","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41416-018-0010-4","volume":"118","author":"CR Marinac","year":"2018","unstructured":"Marinac CR, Birmann BM, Lee IM, Rosner BA, Townsend MK, Giovannucci E, et al. Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. Br J Cancer. 2018;118:1013\u20139.","journal-title":"Br J Cancer"},{"key":"659_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ijc.32109","volume":"145","author":"T Psaltopoulou","year":"2019","unstructured":"Psaltopoulou T, Sergentanis TN, Ntanasis-Stathopoulos I, Tzanninis IG, Riza E, Dimopoulos MA. Anthropometric characteristics, physical activity and risk of hematological malignancies: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2019;145:347\u201359.","journal-title":"Int J Cancer"},{"key":"659_CR12","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/bmt.2014.71","volume":"49","author":"KR Carson","year":"2014","unstructured":"Carson KR, Bates ML, Tomasson MH. The skinny on obesity and plasma cell myeloma: A review of the literature. Bone Marrow Transpl. 2014;49:1009\u201315.","journal-title":"Bone Marrow Transpl"},{"key":"659_CR13","doi-asserted-by":"crossref","unstructured":"Chang SH, Luo S, Thomas TS, O\u2019Brian KK, Colditz GA, Carlsson NP, et al. Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: A population-based cohort study. J Natl Cancer Inst. 2017;109:djw264.","DOI":"10.1093\/jnci\/djw264"},{"key":"659_CR14","doi-asserted-by":"publisher","first-page":"j477","DOI":"10.1136\/bmj.j477","volume":"356","author":"M Kyrgiou","year":"2017","unstructured":"Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, et al. Adiposity and cancer at major anatomical sites: Umbrella review of the literature. BMJ 2017;356:j477.","journal-title":"BMJ"},{"key":"659_CR15","doi-asserted-by":"publisher","first-page":"6615684","DOI":"10.1155\/2021\/6615684","volume":"2021","author":"AD da Cunha J\u00fanior","year":"2021","unstructured":"da Cunha J\u00fanior AD, Zanette DL, Pericole FV, Olalla Saad ST, Barreto Campello Carvalheira J. Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: Could myeloma be prevented with metformin treatment? Adv Hematol. 2021;2021:6615684.","journal-title":"Adv Hematol"},{"key":"659_CR16","doi-asserted-by":"publisher","first-page":"pkz044","DOI":"10.1093\/jncics\/pkz044","volume":"3","author":"CR Marinac","year":"2019","unstructured":"Marinac CR, Suppan CA, Giovannucci E, Song M, Kv\u00e6rner AS, Townsend MK, et al. Elucidating under-studied aspects of the link between obesity and multiple myeloma: weight pattern, body shape trajectory, and body fat distribution. JNCI Cancer Spectr. 2019;3:pkz044.","journal-title":"JNCI Cancer Spectr"},{"key":"659_CR17","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body fatness and cancer-viewpoint of the IARC working group. N Engl J Med. 2016;375:794\u20138.","journal-title":"N Engl J Med"},{"key":"659_CR18","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/leu.2014.34","volume":"28","author":"O Landgren","year":"2014","unstructured":"Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014;28:1537\u201342.","journal-title":"Leukemia."},{"key":"659_CR19","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/bloodadvances.2017007609","volume":"1","author":"M Thordardottir","year":"2017","unstructured":"Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, et al. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: A population-based study. Blood Adv. 2017;1:2186\u201392.","journal-title":"Blood Adv"},{"key":"659_CR20","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","volume":"116","author":"O Landgren","year":"2010","unstructured":"Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood. 2010;116:1056\u20139.","journal-title":"Blood."},{"key":"659_CR21","first-page":"626","volume":"89","author":"MA Thompson","year":"2004","unstructured":"Thompson MA, Kyle RA, Melton LJ 3rd, Plevak MF, Rajkumar SV. Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study. Haematologica. 2004;89:626\u20138.","journal-title":"Haematologica."},{"key":"659_CR22","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1158\/1055-9965.EPI-06-0446","volume":"15","author":"W Cozen","year":"2006","unstructured":"Cozen W, Gebregziabher M, Conti DV, Van Den Berg DJ, Coetzee GA, Wang SS, et al. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomark Prev. 2006;15:2285\u201391.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"659_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/aje\/kwh041","volume":"159","author":"SY Pan","year":"2004","unstructured":"Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y, Canadian Cancer Registries Epidemiology Research G.Association of obesity and cancer risk in Canada. Am J Epidemiol. 2004;159:259\u201368.","journal-title":"Am J Epidemiol"},{"key":"659_CR24","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625\u201338.","journal-title":"N Engl J Med"},{"key":"659_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1023\/A:1008937901586","volume":"12","author":"LM Brown","year":"2001","unstructured":"Brown LM, Gridley G, Pottern LM, Baris D, Swanso CA, Silverman DT, et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control. 2001;12:117\u201325.","journal-title":"Cancer Causes Control"},{"key":"659_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/01.ede.0000172135.61188.2d","volume":"16","author":"CK Blair","year":"2005","unstructured":"Blair CK, Cerhan JR, Folsom AR, Ross JA. Anthropometric characteristics and risk of multiple myeloma. Epidemiology. 2005;16:691\u20134.","journal-title":"Epidemiology."},{"key":"659_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","volume":"21","author":"EW Steyerberg","year":"2010","unstructured":"Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: A framework for traditional and novel measures. Epidemiology. 2010;21:128\u201338.","journal-title":"Epidemiology."},{"key":"659_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr.","year":"1996","unstructured":"Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361\u201387.","journal-title":"Stat Med"},{"key":"659_CR29","doi-asserted-by":"crossref","unstructured":"Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York, NY: Wiley-Interscience; 2000.","DOI":"10.1002\/0471722146"},{"key":"659_CR30","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence\u2014SEER 9 Regs Research Data, Nov 2014 Sub (1973\u20132012) <Katrina\/Rita Population Adjustment>\u2014Linked To County Attributes\u2014Total U.S., 1969\u20132013 Counties, National C. https:\/\/www.seer.cancer.gov."},{"key":"659_CR31","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","volume":"79","author":"RA Kyle","year":"1992","unstructured":"Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O\u2019Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817\u201322.","journal-title":"Blood."},{"key":"659_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2307\/2530817","volume":"39","author":"G Berry","year":"1983","unstructured":"Berry G. The analysis of mortality by the subject-years method. Biometrics. 1983;39:173\u201384.","journal-title":"Biometrics."},{"key":"659_CR33","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00256-016-2425-4","volume":"45","author":"J Veld","year":"2016","unstructured":"Veld J, O\u2019Donnell EK, Reagan MR, Yee AJ, Torriani M, Rosen CJ, et al. Abdominal adipose tissue in MGUS and multiple myeloma. Skelet Radio. 2016;45:1277\u201383.","journal-title":"Skelet Radio"},{"key":"659_CR34","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","volume":"107","author":"O Landgren","year":"2006","unstructured":"Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107:904\u20136.","journal-title":"Blood."},{"key":"659_CR35","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S0140-6736(05)60603-4","volume":"351","author":"G Davey Smith","year":"1998","unstructured":"Davey Smith G, Neaton JD, Wentworth D, Stamler R, Stamler J. Mortality differences between black and white men in the USA: Contribution of income and other risk factors among men screened for the MRFIT. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Lancet. 1998;351:934\u20139.","journal-title":"Lancet."},{"key":"659_CR36","doi-asserted-by":"publisher","first-page":"5872","DOI":"10.1182\/blood-2011-01-330407","volume":"118","author":"JA Fowler","year":"2011","unstructured":"Fowler JA, Lwin ST, Drake MT, Edwards JR, Kyle RA, Mundy GR, et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood. 2011;118:5872\u201382.","journal-title":"Blood."},{"key":"659_CR37","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/oby.21894","volume":"25","author":"JN Hofmann","year":"2017","unstructured":"Hofmann JN, Mailankody S, Korde N, Wang Y, Tageja N, Costello R, et al. Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease. Obesity. 2017;25:1317\u201320.","journal-title":"Obesity."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00659-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00659-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00659-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T15:07:29Z","timestamp":1669216049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00659-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00659-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"assertion":[{"value":"26 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}